ArticleRetrovirology2011
HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Article in Retrovirology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 69 citations in OpenAlex.
- Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals.PLoS pathogens · 2014Trial
- Interactions between HIV proteins and host restriction factors: implications for potential therapeutic intervention in HIV infection.Frontiers in immunology · 2024Review
- Evolutionary plasticity of SH3 domain binding by Nef proteins of the HIV-1/SIVcpz lentiviral lineage.PLoS pathogens · 2021Article
- Residues TRetrovirology · 2021Article
- Review
- In vivo infection dynamics and human adaptive changes of SIVsm-derived viral siblings SIVmac239, SIVFrontiers in virology (Lausanne, Switzerland) · 2021Article
- Article
- Multifaceted Roles of TIM-Family Proteins in Virus-Host Interactions.Trends in microbiology · 2020Review
- TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2.Journal of virology · 2018Article
- Various plus unique: Viral protein U as a plurifunctional protein for HIV-1 replication.Experimental biology and medicine (Maywood, N.J.) · 2017Review
- Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.Journal of virology · 2017Article
- Factors determining human-to-human transmissibility of zoonotic pathogens via contact.Current opinion in virology · 2017Review
- Mucosal stromal fibroblasts markedly enhance HIV infection of CD4+ T cells.PLoS pathogens · 2017Article
- Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane.Frontiers in immunology · 2017Review
- Ion Channel Activity of Vpu Proteins Is Conserved throughout Evolution of HIV-1 and SIV.Viruses · 2016Article
- The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild.Cell host & microbe · 2016Article
- Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.mBio · 2016Article
- The KT Jeang Retrovirology prize 2016: Frank Kirchhoff.Retrovirology · 2016Article
- HIV Vpu Interferes with NF-κB Activity but Not with Interferon Regulatory Factor 3.Journal of virology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundA new subgroup of HIV-1, designated Group P, was recently detected in two unrelated patients of Cameroonian origin. HIV-1 Group P phylogenetically clusters with SIVgor suggesting that it is the result of a cross-species transmission from gorillas. Until today, HIV-1 Group P has only been detected in two patients, and its degree of adaptation to the human host is largely unknown. Previous data have shown that pandemic HIV-1 Group M, but not non-pandemic Group O or rare Group N viruses, efficiently antagonize the human orthologue of the restriction factor tetherin (BST-2, HM1.24, CD317) suggesting that primate lentiviruses may have to gain anti-tetherin activity for efficient spread in the human population. Thus far, three SIV/HIV gene products (vpu, nef and env) are known to have the potential to counteract primate tetherin proteins, often in a species-specific manner. Here, we examined how long Group P may have been circulating in humans and determined its capability to antagonize human tetherin as an indicator of adaptation to humans.
resultsOur data suggest that HIV-1 Group P entered the human population between 1845 and 1989. Vpu, Env and Nef proteins from both Group P viruses failed to counteract human or gorilla tetherin to promote efficient release of HIV-1 virions, although both Group P Nef proteins moderately downmodulated gorilla tetherin from the cell surface. Notably, Vpu, Env and Nef alleles from the two HIV-1 P strains were all able to reduce CD4 cell surface expression.
conclusionsOur analyses of the two reported HIV-1 Group P viruses suggest that zoonosis occurred in the last 170 years and further support that pandemic HIV-1 Group M strains are better adapted to humans than non-pandemic or rare Group O, N and P viruses. The inability to antagonize human tetherin may potentially explain the limited spread of HIV-1 Group P in the human population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.